Pharmacological and Genetic Inhibition of Downstream Targets of P38 MAPK in Experimental Nephrotic Syndrome

American Journal of Physiology - Renal Physiology - United States
doi 10.1152/ajprenal.00207.2017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Physiological Society

Related search

Pharmacological Inhibition of P38 MAPK Reduces Tumor Growth in Patient-Derived Xenografts From Colon Tumors

Oncotarget
Oncology
2015English

P38-Mapk Inhibition and Endotoxin Induced Tubular Dysfunction in Men

Journal of Endotoxin Research
2004English

Molecular and Genetic Basis of Inherited Nephrotic Syndrome

International Journal of Nephrology
Nephrology
2011English

Jejunal Transport in Experimental Nephrotic Syndrome

Pediatric Research
Child HealthPediatricsPerinatology
1983English

P38 MAPK Inhibition Reduces Diabetes-Induced Impairment of Wound Healing

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2010English

Chk1 Inhibition Activates P53 Through P38 MAPK in Tetraploid Cancer Cells

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2008English

ASK1 Inhibition Triggers Platelet Apoptosis via P38-Mapk-Mediated Mitochondrial Dysfunction

Haematologica
Hematology
2019English

Effects of P38 MAPK Inhibition on Early Stages of Diabetic Retinopathy and Sensory Nerve Function

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy